伊曲康唑逆转P388/ADR细胞对柔红霉素的耐药性。
Reversal of daunorubicin resistance in P388/ADR cells by itraconazole.
作者信息
Gupta S, Kim J, Gollapudi S
机构信息
Division of Basic and Clinical Immunology, University of California, Irvine 92717.
出版信息
J Clin Invest. 1991 Apr;87(4):1467-9. doi: 10.1172/JCI115154.
Abstract
Itraconazole is a recently developed triazole antifungal agent that inhibits cell membrane sterol biosynthesis. Itraconazole, in a dose-dependent manner, enhanced intracellular accumulation of daunorubicin and reversed the drug resistance in murine leukemia P388/ADR cells. In addition, itraconazole corrected the altered plasma membrane potentials of P388/ADR cells. The concentrations of itraconazole that reversed drug resistance are comparable to the plasma levels achieved by therapeutic dosage used in the treatment of fungal infections. Therefore, itraconazole is a potential candidate for in vivo use to reverse multidrug resistance in cancer with added benefit of its antifungal property.
摘要
伊曲康唑是一种最近研发的三唑类抗真菌药物，可抑制细胞膜甾醇生物合成。伊曲康唑以剂量依赖的方式增强柔红霉素在细胞内的蓄积，并逆转小鼠白血病P388/ADR细胞的耐药性。此外，伊曲康唑纠正了P388/ADR细胞改变的质膜电位。逆转耐药性的伊曲康唑浓度与治疗真菌感染所用治疗剂量所达到的血浆水平相当。因此，伊曲康唑是体内逆转癌症多药耐药性的潜在候选药物，且具有抗真菌特性这一额外益处。
相似文献
1
Reversal of daunorubicin resistance in P388/ADR cells by itraconazole.伊曲康唑逆转P388/ADR细胞对柔红霉素的耐药性。
J Clin Invest. 1991 Apr;87(4):1467-9. doi: 10.1172/JCI115154.
2
3
Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate.马来酸哌克昔林逆转P388小鼠白血病细胞对阿霉素的获得性耐药
Cancer Res. 1984 Jan;44(1):144-8.
4
Promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs.钙拮抗剂硫氮䓬酮及其类似物对柔红霉素摄取和毒性的促进作用。
Cancer Treat Rep. 1985 Jun;69(6):673-6.
5
Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists.P388小鼠白血病中的蒽环类药物耐药性及其通过钙拮抗剂的克服。
Cancer Res. 1985 Apr;45(4):1687-91.
6
Isolation of highly multidrug-resistant P388 cells from drug-sensitive P388/S cells by flow cytometric cell sorting.通过流式细胞术细胞分选从药物敏感的P388/S细胞中分离出高度耐多药的P388细胞。
Cytometry. 1988 Jul;9(4):359-67. doi: 10.1002/cyto.990090413.
7
Exploring multidrug resistance using rhodamine 123.使用罗丹明123探索多药耐药性。
Cancer Commun. 1989;1(3):145-9.
8
9
Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.对阿霉素的多因素抗性：阿霉素敏感和抗性P388白血病克隆细胞系中DNA修复、谷胱甘肽转移酶活性、药物外排和P-糖蛋白的关系。
Cancer Res. 1988 Jul 1;48(13):3595-602.
10
Characterization of multidrug resistance by fluorescent dyes.通过荧光染料对多药耐药性进行表征。
Cancer Res. 1991 Sep 1;51(17):4665-70.
引用本文的文献
1
The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive.OSR9 方案：一种使用来自普通医学的九种老药抑制生长驱动的骨肉瘤治疗新增强策略。
Int J Mol Sci. 2023 Oct 23;24(20):15474. doi: 10.3390/ijms242015474.
2
Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer.伊曲康唑可逆转前列腺癌中ABCB1介导的多西他赛耐药性。
Front Pharmacol. 2022 Jun 3;13:869461. doi: 10.3389/fphar.2022.869461. eCollection 2022.
3
Induced Cell Cycle Arrest in Triple-Negative Breast Cancer by Combined Treatment of Itraconazole and Rapamycin.伊曲康唑与雷帕霉素联合治疗诱导三阴性乳腺癌细胞周期停滞
Front Pharmacol. 2022 Apr 19;13:873131. doi: 10.3389/fphar.2022.873131. eCollection 2022.
4
Repurposing itraconazole for the treatment of cancer.重新利用伊曲康唑治疗癌症。
Oncol Lett. 2017 Sep;14(3):2587-2597. doi: 10.3892/ol.2017.6569. Epub 2017 Jul 10.
5
Repurposing itraconazole as an anticancer agent.将伊曲康唑重新用作抗癌剂。
Oncol Lett. 2017 Aug;14(2):1240-1246. doi: 10.3892/ol.2017.6325. Epub 2017 Jun 7.
6
Increased lanosterol turnover: a metabolic burden for daunorubicin-resistant leukemia cells.羊毛甾醇周转率增加：柔红霉素耐药白血病细胞的代谢负担
Med Oncol. 2016 Jan;33(1):6. doi: 10.1007/s12032-015-0717-5. Epub 2015 Dec 23.
7
Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.肿瘤学中药物的重新利用（ReDO）——伊曲康唑作为一种抗癌药物。
Ecancermedicalscience. 2015 Apr 15;9:521. doi: 10.3332/ecancer.2015.521. eCollection 2015.
8
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.复发性胶质母细胞瘤的CUSP9*治疗方案：阿瑞匹坦、青蒿琥酯、金诺芬、卡托普利、塞来昔布、双硫仑、伊曲康唑、利托那韦、舍曲林联合持续低剂量替莫唑胺。
Oncotarget. 2014 Sep 30;5(18):8052-82. doi: 10.18632/oncotarget.2408.
9
Interaction of common azole antifungals with P glycoprotein.常见唑类抗真菌药与P糖蛋白的相互作用。
Antimicrob Agents Chemother. 2002 Jan;46(1):160-5. doi: 10.1128/AAC.46.1.160-165.2002.
10
Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.抗真菌药物对氧化药物代谢的影响：临床相关性。
Clin Pharmacokinet. 2000 Feb;38(2):111-80. doi: 10.2165/00003088-200038020-00002.
本文引用的文献
1
Ketoconazole and cyclosporin.
Lancet. 1982 Nov 27;2(8309):1217. doi: 10.1016/s0140-6736(82)91231-4.
2
Itraconazole, a new triazole that is orally active in aspergillosis.伊曲康唑，一种对曲霉病有口服活性的新型三唑类药物。
Antimicrob Agents Chemother. 1984 Oct;26(4):527-34. doi: 10.1128/AAC.26.4.527.
3
Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma.环孢素A可纠正艾氏腹水癌对柔红霉素的耐药性。
Br J Cancer. 1986 Aug;54(2):235-8. doi: 10.1038/bjc.1986.167.
4
Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.环孢素A在体外可逆转急性淋巴细胞白血病对长春新碱和柔红霉素的耐药性。
J Clin Invest. 1986 Apr;77(4):1405-8. doi: 10.1172/JCI112450.
5
Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells. Lack of correlation between cellular doxorubicin levels and expression of resistance.钙调蛋白抑制剂三氟拉嗪对多柔比星在逐渐产生多柔比星耐药的L1210小鼠白血病细胞中的细胞蓄积、滞留及细胞毒性的调节作用存在差异。细胞内多柔比星水平与耐药性表达之间缺乏相关性。
Biochem Pharmacol. 1988 Jan 15;37(2):185-93. doi: 10.1016/0006-2952(88)90716-2.
6
Sterol biosynthesis inhibitors. Secondary effects and enhanced in vivo efficacy.
Ann N Y Acad Sci. 1988;544:338-47. doi: 10.1111/j.1749-6632.1988.tb40418.x.
7
Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.钙调蛋白抑制剂三氟拉嗪在体外和体内对阿霉素细胞毒性而非细胞水平的调节作用取决于耐药水平。
Br J Cancer. 1988 Sep;58(3):335-40. doi: 10.1038/bjc.1988.214.
8
Correction of altered plasma membrane potentials. A possible mechanism of cyclosporin A and verapamil reversal of pleiotropic drug resistance in neoplasia.
Cancer Chemother Pharmacol. 1988;22(2):163-8. doi: 10.1007/BF00257315.
9
Resistance to multiple chemotherapeutic agents in human cancer cells.人类癌细胞对多种化疗药物的耐药性。
Trends Pharmacol Sci. 1988 Feb;9(2):54-8. doi: 10.1016/0165-6147(88)90117-4.
10
First International Symposium on Itraconazole. Oaxaca, Mexico, October 7-8, 1985. Proceedings.
Rev Infect Dis. 1987 Jan-Feb;9 Suppl 1:S1-152.
Zotero 插件